| | |
| Clinical data | |
|---|---|
| Trade names | Medi-Exametazim |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C13H25N4O3Tc |
| Molar mass | 383 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | racemic |
| |
| | |
Technetium (99mTc) exametazime is a radiopharmaceutical sold under the trade name Ceretec, and is used by nuclear medicine physicians for the detection of altered regional cerebral perfusion in stroke [1] and other cerebrovascular diseases. It can also be used for the labelling of leukocytes to localise intra-abdominal infections [2] and inflammatory bowel disease. [3] Exametazime (the part without technetium) is sometimes referred to as hexamethylpropylene amine oxime or HMPAO, although correct chemical names are: [4]
The drug consists of exametazime as a chelating agent for the radioisotope technetium-99m. Both enantiomeric forms of exametazime are used—the drug is racemic. [5] The third stereoisomer of this structure, the meso form, is not included.